ReviewCancers2019
Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Assessment of Ablation Therapy in Pancreatic Cancer: The Radiologist's Challenge.Frontiers in oncology · 2020Pooled it
- Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound-guided primary biliary drainage for malignant distal biliary obstruction: a review.Clinical endoscopy · 2026Review
- Article
- Case Report: Late repeat pancreatic irreversible electroporation in the long-term multidisciplinary management of unresectable pancreatic ductal adenocarcinoma.Frontiers in oncology · 2026Article
- Excellent Survival Outcome in a Patient Receiving NALIRIFOX for Metastatic Pancreatic Adenocarcinoma: A Case Report.Oncology research · 2026Article
- Diagnosis and Surgical Management for Advanced Pancreatic Cancer Requiring Vascular Resection.Diagnostics (Basel, Switzerland) · 2025Review
- Short cold atmospheric plasma treatment preserves vascular quiescence in 3D tumor-stroma-endothelial models of pancreatic cancer in vitro and in ovo.NPJ precision oncology · 2025Article
- Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases.Annals of medicine · 2025Article
- Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2025Article
- Development of scoring models to predict early pancreatic cancer risk in new-onset diabetes mellitus patients.Hepatobiliary surgery and nutrition · 2025Article
- Neoadjuvant Stereotactic Ablative Radiotherapy in Pancreatic Ductal Adenocarcinoma: A Review of Perioperative and Long-Term Outcomes.Diseases (Basel, Switzerland) · 2025Review
- Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy.European journal of clinical nutrition · 2025Article
- An 81-Year-Old Geriatric Patient with Metastatic Pancreatic Cancer Demonstrating Excellent Response and Well Tolerance to NALIRIFOX: A Case Report and Literature Review.Reports (MDPI) · 2025Article
- Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience.Mutagenesis · 2025Article
- Review
- Synchronized Contrast-Enhanced 4DCT Simulation for Target Volume Delineation in Abdominal SBRT.Cancers · 2024Article
- Curative intent treatment for pancreatic duct adenocarcinoma invade superior mesenteric vein.Radiology case reports · 2024Article
- Management of distal cholangiocarcinoma with arterial involvement: Systematic review and case series on the role of neoadjuvant therapy.World journal of gastrointestinal surgery · 2024Article
- Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer.Cancers · 2024Review
- Combination of modified FOLFIRINOX with stereotactic body radiotherapy as an induction therapy for locally advanced pancreatic adenocarcinoma - a prospective single-arm study.Contemporary oncology (Poznan, Poland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 3 countries.
Funding
Abstract
Locally advanced pancreatic cancer (LAPC) has several definitions but essentially is a nonmetastasized pancreatic cancer, in which upfront resection is considered not beneficial due to extensive vascular involvement and consequent high chance of a nonradical resection. The introduction of FOLFIRINOX chemotherapy and gemcitabine-nab-paclitaxel (gem-nab) has had major implications for the management and outcome of patients with LAPC. After 4-6 months induction chemotherapy, the majority of patients have stable disease or even tumor-regression. Of these, 12 to 35% are successfully downstaged to resectable disease. Several studies have reported a 30-35 months overall survival after resection; although it currently remains unclear if this is a result of the resection or the good response to chemotherapy. Following chemotherapy, selection of patients for resection is difficult, as contrast-enhanced computed-tomography (CT) scan is unreliable in differentiating between viable tumor and fibrosis. In case a resection is not considered possible but stable disease is observed, local ablative techniques are being studied, such as irreversible electroporation, radiofrequency ablation, and stereotactic body radiation therapy. Pragmatic, multicenter, randomized studies will ultimately have to confirm the exact role of both surgical exploration and ablation in these patients. Since evidence-based guidelines for the management of LAPC are lacking, this review proposes a standardized approach for the treatment of LAPC based on the best available evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.